Aim: To evaluate the prevalence and predictors of potentially inappropriate medications (PIM) and potential prescribing omissions (PPO) in hospital-discharged older patients, according to the recently updated Screening Tool of Older People's Prescriptions and Screening Tool to Alert to Right Treatment version 2 criteria.
Introduction
The growing burden of chronic diseases occurring with advancing age frequently leads to complex therapies. Polypharmacy and inappropriate prescribing (IP) are well-known risk factors for adverse drug events (ADE), which commonly cause unfavorable clinical outcomes in older people.
1,2 IP is highly prevalent among older adults, and has been associated with polypharmacy, advanced age, higher comorbidity burden and female sex. [3] [4] [5] Several tools have been developed to optimize medical therapy in older patients, including the Beers criteria and the Screening Tool of Older People's Prescriptions and Screening Tool to Alert to Right Treatment (STOPP/START) criteria. 6 The Beers criteria were the first comprehensive list of drugs to be avoided in older patients; since their first publication in 1991, they have been extensively used worldwide and have periodically been updated, until the last version of 2015. 7 In a previous study using the 2015 Beers criteria, 8 we reported a 63% prevalence of potentially inappropriate medications (PIM) in hospital-discharged older patients. PIM were independently associated with psychiatric-behavioral disorders, number of medications and long-term care facility discharge, whereas a better functional status was protective. However, PIM were not associated with re-hospitalization or death at 6 months. 8 Nevertheless, the Beers criteria have restricted applicability in European countries, as several drugs listed are unavailable there; furthermore, they overlook other aspects of IP, such as potential prescribing omissions (PPO) and duplicated prescriptions. The STOPP/START criteria were developed and validated by a panel of European experts in 2008; 9 their updated version (STOPP/START v2) was published in 2015 based on expanded scientific evidence. 10 The STOPP/START criteria recognize the dual nature of IP by including a list of conditions in which specific drugs might represent a PIM (STOPP criteria) or a PPO (START criteria). PIM identified according to STOPP criteria, but not according to Beers criteria, have been associated with ADE; furthermore, the application of STOPP/START criteria once during hospitalization in older people significantly improves medication appropriateness and reduces ADE. 11 Several studies have investigated the factors associated with PIM, yielding discordant results between and within different clinical settings; polypharmacy has been the most consistent, although it is not a univocal definition. 11 Variables associated with PPO have been less extensively investigated, but advancing age and higher comorbidity burden are frequently encountered, whereas the association with polypharmacy is controversial. 12, 13 Few studies have investigated the prevalence of PIM and PPO according to STOPP/START v2, mainly retrospectively on community-dwellers. [14] [15] [16] The present two-phase prospective observational study aimed to evaluate the prevalence, predictors and potential clinical implications (death and readmissions) of IP according to STOPP/START v2 among hospital-discharged older patients. In this study, we report the results of the cross-sectional part of the study.
Methods
The present study was carried out according to the Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects, and reported conforming to the Strengthening The Reporting of Observational Studies in Epidemiology statements. 17 Signed informed consent was obtained by patients, or by proxies or caregivers for patients unable to express consent.
Study design, setting and participants
A prospective cohort observational study involving three internal medicine and two geriatric wards of two teaching hospitals in north-western Italy (A.O.U. Città della Salute e della Scienza, Turin, and A.O. Santa Croce e Carle, Cuneo) was carried out. Patients aged ≥65 years consecutively discharged between March 2017 and June 2017 were enrolled. Exclusion criteria were: inhospital death, refusal to sign informed consent, incomplete data and previous enrolment. Data were collected on a standardized form by four resident fellows under the supervision of two senior geriatricians, through direct interview and review of clinical records.
Application of the STOPP/START criteria
STOPP/START v2 consists of 80 STOPP criteria and 34 START criteria, organized according to physiological system. 10 PIM at discharge were identified by applying the full list of STOPP v2 criteria. The STOPP A category includes two implicit rules, which are "drugs prescribed without a clinical indication" and "drugs prescribed beyond the recommended duration." The application of these criteria was evaluated case-by-case by two investigators, and the implicated medications were recorded. PPO were detected by applying the START v2 criteria. Because of the acute inpatient setting of the study, it was not possible to carry out a thorough evaluation to determine the type and severity of dementia, and thus to establish the potential indication to acetylcholinesterase inhibitors (START C3). Also, potential indications to eye drops for open angle glaucoma (START C4) and vaccines (START I) were not assessed in the study. Furthermore, any type of laxative was considered as a fiber supplement (START D2). In the application of START A5 criteria, end-of-life status was defined according to the Canadian Study of Health and Aging (CSHA) scale (i.e. CSHA = 9). 18 Primary goal: Prevalence of IP The prevalence of PIM was defined as the proportion of patients presenting at least one PIM at discharge. Similarly, the prevalence of PPO was calculated. PIM and PPO were considered altogether as IP.
Secondary goal: Variables associated with IP
The main demographic and clinical variables were recorded for each patient, including serum creatinine and bodyweight to estimate the glomerular filtration rate according to the CockcroftGault formula, and the number of drugs at discharge. Polypharmacy was defined as the prescription of five or more drugs, and excessive polypharmacy as >10 drugs. 19 Every patient underwent a
Comprehensive Geriatric Assessment, including the Short Portable Mental Status Questionnaire (SPMSQ), 20 Katz index for Activities of Daily Living (ADL), 21 Instrumental Activities of Daily Living scale (IADL) 22 and CSHA. 18 Moderate-to-severe cognitive impairment was identified by SPMSQ scores ≥5. Patients were considered dependent in ADL with three or more lost functions, and partially or not autonomous in IADL with scores ≤9. A CSHA score of ≥5 identified frail patients. Comorbidities were grouped according to Cumulative Illness Rating Scale (CIRS) classes; the CIRS-Severity Index (CIRS-SI, the mean score of the first 13 items) and the CIRS-Comorbidity Index (CIRS-CI, the number of items with a score ≥3) were calculated. 23 The main diagnosis at discharge was also recorded.
Statistical analysis
Absolute and relative frequencies of dichotomous and categorical variables, and either the mean and standard deviation or median and interquartile range of continuous variables were calculated, as appropriate. Differences between patients discharged from geriatric and internal medicine wards were explored using the χ 2 -test for dichotomous and categorical variables, and ANOVA or MannWhitney test for normally distributed and not normally distributed continuous variables, respectively. To identify variables independently associated with PIM and PPO, a multivariate logistic regression analysis (stepwise method) was carried out, where an inappropriate prescribing indicator (either a PIM or a PPO) was the dependent variable, and sociodemographic variables, geriatric conditions and the number of medications at discharge were the independent variables. Adjusted odds ratios (OR) and their 95% confidence intervals (CI) were calculated. Statistical analysis was carried out using MedCalc Statistical Software 9.3.7.0 (MedCalc Software BVBA, Ostend, Belgium). Statistical significance was set at P < 0.05.
Results

Population characteristics
We enrolled 726 patients in the study. Table 1 reports the demographic and clinical variables of the overall sample, and according to geriatric and internal medicine discharge. The mean age was 81.5 years, and 47.8% of patients were women, with a high prevalence of functional impairment. The vast majority of patients were partially or not autonomous in IADL (72.6%) and almost half of them were dependent in ADL (47.4%). Frailty was frequent (72.6%), and 28.5% of patients presented moderate-to-severe cognitive impairment. Polypathology was common, with a mean of almost five diseases requiring an active treatment per patient, the most prevalent being hypertension (66%), cardiac (62.7%) and vascular/hematological diseases (47.5%). The most frequent diagnoses at discharge were heart failure (16.8%), pneumonia or acute bronchitis (14.8%), sepsis or non-respiratory infectious diseases (14.3%), and dementia or psychiatric disorders (7.9%). The mean number of medications at discharge was 7.5 AE 3.2, with 82.4% of patients being prescribed five or more drugs.
list of the encountered PIM and PPO, see Table S1 ). At least one IP was present in 70.4% of patients.
The prevalence of PIM was 54.4%; one, two and three or more PIM were found in 27.2%, 17.2% and 10% of patients, respectively. The prevalence of PPO was 44.5%; one, two and three or more PPO were found in 28.1%, 10.1% and 6.3% of patients, respectively. Patients discharged from internal medicine wards had a higher prevalence of IP compared with those discharged from geriatric wards (Table 1) , as considered both as PIM (63.8% vs 45.1%) and as PPO (53.9% vs 35.2%). Figure 1 shows the prevalence of PIM, PPO and IP according to the number of drugs prescribed at discharge.
PIM
The most frequently observed PIM (Table 2) involved benzodiazepines (due to their intrinsic property of increasing the risk of falls, STOPP K1-18.5%, and when used for periods >4 weeks, STOPP D5-15.6%) and drugs used without an evidence-based indication (STOPP A1 9%), mainly represented by proton-pump inhibitors (PPI), in 52 out of 65 cases. Figure 2a shows the absolute and relative frequencies of PIM according to STOPP categories, most frequently regarding drugs that increase fall risk (STOPP K), drugs for the central nervous system (STOPP D) and for the cardiovascular system (STOPP B), altogether representing 65.4% of total PIM.
PPO
The most frequently encountered PPO (Table 2) involved 5-alpha reductase inhibitors (START G2 10.2%), angiotensin-converting enzyme inhibitors (START A6 9.4%), statins (START A5 6.7%), and drugs for the treatment and prevention of osteoporosis (vitamin D in osteopenia, falls and housebound patients, START (Fig. 2b) , PPO were most frequently observed for cardiovascular (37.1%), musculoskeletal (25%) and urogenital (18.3%) systems.
Variables associated with PIM and PPO
After multivariate analysis (Table 3) , the only variable positively associated with PIM was a higher number of medications at discharge (OR 1.22, 95% CI 1.15-1.28), whereas a negative association was observed between PIM and discharge from geriatric wards (OR 0.55, 95% CI 0.40-0.75). Older age, ADL dependence, a higher number of medications at discharge and CIRS-CI were positively associated with PPO, whereas frailty and geriatric discharge were negatively associated with them (Table S2) . To test the strength of these latter findings, we repeated the multivariate analysis excluding terminally ill patients ( Figure 1 The prevalence of potentially inappropriate medication (PIM), potential prescribing omission (PPO) and inappropriate prescribing (IP) according to the number of drugs at discharge. P for trend <0.0001 for each category. *P < 0.001, **P < 0.0001. 
Discussion
The main findings of the present study were: (i) there was a high prevalence of IP (70%) among hospital-discharged older patients, with PIM being more common than PPO (54.4% vs 44.5%); (ii) commonly detected PIM included benzodiazepines and PPI, whereas PPO were frequently related to 5-alpha reductase inhibitors, angiotensin-converting enzyme inhibitors, statins and drugs for osteoporosis; and (iii) a higher number of drugs at discharge was strongly associated with PIM and PPO, whereas geriatric discharge was protective for both.
Few studies have investigated the prevalence of PIM and PPO according to STOPP/START v2. The results of the present study are in keeping with those reported in two recent studies carried out in hospital-discharged patients. Among 276 patients (mean age 74 years) discharged from an internal medicine department, Mucalo et al. reported a PIM prevalence of 68.8%; mainly represented by benzodiazepines and PPI. 24 In a sample of 319 patients (mean age 69 years) discharged from the cardiology and internal medicine departments of an Albanian hospital, 63.0% of patients presented at least one PIM, a figure similar to what we detected among internal medicine-discharged patients (63.8%). 25 Lower prevalences of PIM and PPO (12.9% and 22.2%, respectively) were observed in 532 community-dwelling patients (mean age 75 years) from three European countries. 15 In keeping with previous studies, benzodiazepines and PPI were the most frequent PIM in our sample. 8, 24, 26 Interestingly, in N.A.
7.3%
18,3% our sample, PPI inappropriateness was more often related to the lack of an evidence-based indication (STOPP A1), rather than to an inappropriate duration of appropriate therapy (STOPP F2). A similar finding was reported in a survey on PPI use among hospital-discharged adults, showing an unapproved or unknown PPI indication in 18.8% and 14.6% of patients, respectively. 27 Altogether, these findings might have clinical relevance considering the potential detrimental effects of these drugs. 28 The association between a higher number of drugs and IP has been extensively reported in the literature. 3, 4, 29 Adherence to disease-focused guidelines in patients with polypathology and knowledge gaps in appropriate prescribing for older patients are often advocated as the main reasons explaining this association. 30 More controversial is the association between underprescription and polypharmacy: indeed, most of the studies that have investigated IP have not considered PPO. In our sample, PPO were significantly associated with older age and a higher number of medications, whereas geriatric discharge was associated with a reduced prevalence of PPO. The present findings are in keeping with a recent study from Blanco-Reina et al., who reported a clear association between polypharmacy and PPO. 12 The main classes of drugs accounting for PPO in the present study included 5-alpha reductase inhibitors in prostatism, angiotensin-converting enzyme inhibitors in heart failure with reduced ejection fraction, statins in secondary prevention of cardiovascular disease, and drugs for the treatment and prevention of osteoporosis. A possible explanation for these omissions within the context of polytherapy might be the reluctance of physicians to add further medications, mainly perceived as long-term prevention strategies, to an already long prescription list. On the other side, the small but significant association of older age with PPO (but not with PIM) might suggest an ageist attitude of some prescribers. Eventually, the association of polypharmacy with PPO might be explained as lack of care in prescribing for older patients.
To date, few studies have investigated IP in both geriatric and internal medicine wards. In a previous study we carried out in the same participating units, the prevalence of PIM identified according to the Beers criteria was similar in patients discharged from geriatric and internal medicine wards (64.2% vs 61.3%; rising to 80.4% vs 84.7%, when including drugs to be used with caution). Conversely, in the present study, the prevalence of IP was significantly higher among patients discharged from internal medicine wards than in those discharged from geriatric wards, both for PIM (63.8% vs 45.1%) and for PPO (53.9% vs 35.2%). Although the Beers criteria are an inherent part of the cultural background of geriatricians across the world, Italian as well as most European geriatricians are more used to tailoring their prescriptions according to the STOPP/ START criteria. Indeed, it is worth noting that the prevalence of PIM in internal medicine wards is almost identical (approximately 64%) in both studies, either using the Beers criteria or the STOPP/ START criteria, whereas PIM were remarkably lower in geriatric wards when using the STOPP/START criteria.
To the best of our knowledge, this is the first study to assess and compare the prevalence and type of PIM and PPO using the STOPP/START v2 criteria in a sample of older patients discharged from geriatric and internal medicine wards. In our view, the present study has some important strengths. First, the prospective collection of clinical and demographic variables of interest (including the glomerular filtration rate) allowed us to apply the full set of STOPP criteria and to carry out a Comprehensive Geriatric Assessment of each patient, also in internal medicine wards, where it is not routinely carried out. The inclusion of specific domains from the Comprehensive Geriatric Assessment (frailty, functional and cognitive statuses, comorbidity) in the multivariate analysis bestows clinical robustness to the present findings. Furthermore, this is one of the first studies comparing prescribing attitudes between geriatric and internal medicine wards. The evidence of a higher prevalence of PIM and PPO at discharge in internal medicine than in geriatric wards should not come as a surprise, as it is expected among physicians culturally more skilled in the care of older patients. Present findings might have important clinical implications, as internists, as well as geriatricians, are on the frontline of care for older inpatients. However, whether IP is associated with more frequent adverse clinical outcomes has to be shown, and will be investigated in the follow up of the present study.
A limitation of the present study was that these findings, obtained in a sample of vulnerable hospital-discharged older patients, are not generalizable to community-dwelling older adults, who usually present better overall health status. Second, despite an accurate retrieval of clinical documentation, it is not possible to exclude that unreported medical conditions might be responsible for prescriptions identified as PIM. Furthermore, patients were enrolled regardless of discharge diagnosis and estimated life expectancy. Is it possible that part of the detected PPO, occurring in terminally ill patients, should not be considered as inappropriate. However, variables independently associated with PPO were similar and consistent when multivariate analysis was repeated excluding terminally ill patients. Finally, as underlined by other authors, some criteria are not completely explicit (e.g. STOPP C1 "long-term aspirin at doses >160 mg/day" does not define "long term"), thus requiring a subjective judgment. 15 In conclusion, the present findings highlight that IP is highly prevalent among older hospital-discharged patients. Polypharmacy is associated with IP, considered both as PIM and as PPO, whereas geriatric discharge seems to be protective. Follow-up data will clarify the impact of IP on relevant clinical outcomes, such as death and re-hospitalization.
Supporting information
Additional supporting information may be found in the online version of this article at the publisher's website:
Full list of observed potentially inappropriate medications and potential prescribing omissions according to Screening Tool of Older People's Prescriptions and Screening Tool to Alert to Right Treatment version 2 criteria in the overall study sample (n = 726). ACEi, angiotensin converting enzyme inhibitor; AChEi, acetylcholinesterase inhibitor; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BB, beta-blocker; BDZ, benzodiazepine; BMD, bone mineral density; BPSD, behavioral and psychological symptoms of dementia; CCB, calcium channel blocker; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; COX-2, cyclooxygenase type 2; CS, corticosteroid; DA, dopamine agonist; DBP, diastolic blood pressure; DM, diabetes mellitus; DMARD, disease-modifying antirheumatic drug; DTI, direct thrombin inhibitor; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; FEV1, forced expiratory volume in the first second; FXaI, factor X-activated inhibitor; GI, gastrointestinal; GERD, gastroesophageal reflux disease; H2, histamine receptor type 2; HF, heart failure; HTN, hypertension; LD, loop diuretic; L-DOPA, levodopa; LTOT, long-term oxygen therapy; mo, months; MRA, mineralocorticoid receptor antagonist; N.A., not applicable; NHYA, New York Heart Association; NLT, neuroleptic; NSAID, non-steroidal anti-inflammatory drug; PDE-5, phosphodiesterase type 5; PE, pulmonary embolism; PIM, potentially inappropriate medication; PPI, proton pump inhibitor; PPO, potential prescribing omission; PUD, peptic ulcer disease; SBP, systolic blood pressure; SNRI, serotonin/norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; VKA, vitamin K antagonist.
Table S2
Variables independently associated with potential prescribing omissions in the overall study sample (n = 726), including terminally ill patients. ADL, activities of daily living; CI, confidence interval; CIRS, cumulative illness rating scale; OR, odds ratio; PPO, potential prescribing omission; SE, standard error. 
